All In Biotech

Drug Trial Radar · NCT06948292

Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics

Role of QRX-3 a Novel NAD Modulator in Ambulatory Chronic Kidney Patients

Last checked: Nov 19, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

127

Actual

Start

Mar 1, 2023

Primary completion

Aug 30, 2024

Study completion Oct 30, 2024

Sponsor

Lead sponsor
Ebima Clifford OkundayeIndustry
Sponsor type
Industry
First posted
Apr 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
Double (care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

QRX-3, a new drug that stabilized the kidney renal tubular cell and increase the activity of NAD ( nicotinamide adenine dineuclotide )within the kidney cells; leading to decrease oxidative changes intracellularly, repair of renal tubular injury and restoration of optimized renal function above baseline , will be studied in patients with progressive chronic kidney disease over 12 months . The result of the change in renal function expressed as creatinine GFR (Glomerular filtration decline) over the treatment duration will be compared in the treatment group will be compared to control group without the medication during that same period .

Conditions

  • Chronic Kidney Disease Stages 3-5
  • Diabetic Kidney Disease
  • Hypertensive Kidney Disease

Interventions

  • QRX-3Drug

    phase 2B CKD study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. daily change in glomerular filtration rate by creatinine in mls/minTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Neukidney Inc

    Pasedena, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.